Table 1 Characteristics of the study cohort.
Total (151) | Rejectors (40) | Non-rejectors (111) | p-value | |
|---|---|---|---|---|
Sex (Male) | 110 (72.9%) | 29 (72.5%) | 81 (73%) | 0.99 |
Age (Years) | 59 (52–64) | 58(51–64) | 59(54–64) | 0.68 |
Primary Disease | 0.89 | |||
Alcohol | 56(37.1%) | 14(36.8%) | 42(37.2%) | 0.71 |
HCV | 21(13.9%) | 4 (10.5%) | 17(15%) | 0.33 |
HBV | 15(9.9%) | 5(13.2%) | 10(8.9%) | 0.41 |
Autoimmune | 14(9.3%) | 5(13.2%) | 9(8%) | 0.35 |
Cholestatic | 9(6%) | 3(7.9%) | 6(5.3%) | 0.55 |
Cryptogenic | 5(3.3%) | 1(2.6%) | 4(3.5%) | 0.51 |
MASLD | 13(8.6%) | 2(5.3%) | 11 (9.7%) | 0.73 |
Others | 18(11.9%) | 4(10.3%) | 14(12.4%) | 0.72 |
HCC | 54 (35.8%) | 22(55%) | 32(28.8%) | 0.004 |
Donor type (DBD) | 101(68.2%) | 29(72.5%) | 72(66.7%) | 0.55 |
Donor age (Years) | 58 (48–68) | 55(42–69) | 58(50–68) | 0.19 |
Ischemia time (min) | 395(343–470) | 390(360–480) | 398(340–466) | 0.50 |
IS protocol | 0.06 | |||
Double | 42 (27.8%) | 16 (38.1%) | 26 (23.4%) | |
Triple | 109 (72.2%) | 24 (60%) | 85 (76.6%) | |
CMV infections | 29 (19.2%) | 3 (7.5%) | 26 (23.4%) | 0.03 |
Biliary strictures | 26 (17.2%) | 6 (15%) | 20 (18%) | 0.78 |
